Evidence map›Paper›PMID 16325700›Full record

ReviewLancet (London, England)2005

Marfan's syndrome.

Daniel P Judge, Harry C Dietz

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Lancet (London, England), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03236571 (Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome), which is not on this map. Cited by 459 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
459citing papers in PubMed, 4 pooled it
22.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03236571 nacompletednot on this mapstarted 2018, after this paper: background citation

Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome: an Interventional, Prospective, Monocentric Study.

TypeinterventionalSponsorUniversity Hospital, ToulouseRan2018 to 2022Enrolled28ConditionsMarfan SyndromeArmsRehabilitation program
3 · Its place in the literature

Who cites it

459 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,174 citations in OpenAlex.

  1. Skeletal muscle alterations in Marfan syndrome: a systematic review.Journal of muscle research and cell motility · 2025
    Pooled it
  2. Pooled it
  3. Oral Health Status in Marfan Syndrome: A Systematic Review and Meta-Analysis of 353 Cases.International journal of environmental research and public health · 2022
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. D-dimer in Marfan syndrome: effect of obstructive sleep apnea induced blood pressure surges.American journal of physiology. Heart and circulatory physiology · 2022
    Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Assessment of Hip Joint Articular Cartilage Composition in People with Marfan Syndrome Utilizing T1ρ and T2 Mapping.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2026
    Article
  20. Fibronectin-induced overactivation of αNature communications · 2026
    Article

399 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Daniel P JudgeDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Harry C Dietz
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Pathogenesis and Therapy of Marfan Vascular DiseaseK08HL067056 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI JUDGE, DANIEL P · 2003 to 2007
$657k
NHLBI NIH HHS K08 HL067056
6 · The paper itself

Abstract

Marfan's syndrome is a systemic disorder of connective tissue caused by mutations in the extracellular matrix protein fibrillin 1. Cardinal manifestations include proximal aortic aneurysm, dislocation of the ocular lens, and long-bone overgrowth. Important advances have been made in the diagnosis and medical and surgical care of affected individuals, yet substantial morbidity and premature mortality remain associated with this disorder. Progress has been made with genetically defined mouse models to elucidate the pathogenetic sequence that is initiated by fibrillin-1 deficiency. The new understanding is that many aspects of the disease are caused by altered regulation of transforming growth factor beta (TGFbeta), a family of cytokines that affect cellular performance, highlighting the potential therapeutic application of TGFbeta antagonists. Insights derived from studying this mendelian disorder are anticipated to have relevance for more common and non-syndromic presentations of selected aspects of the Marfan phenotype.

Indexed as

Marfan SyndromeAdipokinesAdrenergic beta-AntagonistsAnimalsClinical Trials as TopicDiagnosis, DifferentialFemaleFibrillin-1FibrillinsHumansMaleMiceMicrofilament ProteinsAdipokinesAdrenergic beta-AntagonistsFBN1 protein, humanFbn1 protein, mouseFibrillin-1FibrillinsMicrofilament Proteins

Identifiers

PMID16325700
PMCPMC1513064
OpenAlexW2131202416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.